T. Verhulst

发表

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

Italo Poggesi, Vineet Pande, James P. Edwards, 2017 .

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Bie M. P. Verbist, U. Philippar, T. Graubert, 2021, Molecular Cancer Therapeutics.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

C. Murray, J. Vialard, D. Newell, 2017, Molecular Cancer Therapeutics.

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

M. Janicot, L. Andries, J. Arts, 2003, Journal of Pharmacology and Experimental Therapeutics.

A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib

J. Pérez-Ruixo, P. Magni, J. Vialard, 2021, Cancer Chemotherapy and Pharmacology.

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer

J. Werbeck, T. Casneuf, A. Axel, 2016, Breast cancer.

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Tianbao Lu, G. Clack, L. Mevellec, 2018, Experimental and Molecular Therapeutics.

Abstract 1738: JNJ-42756493 is an inhibitor of FGFR-1, 2, 3and4 with nanomolar affinity for targeted therapy

C. Murray, J. Vialard, D. Newell, 2014 .

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

M. Janicot, L. Andries, J. Arts, 2003, Journal of Pharmacology and Experimental Therapeutics.